TOKYO -- A Japanese Nobel laureate is demanding more money for his role in developing the breakthrough cancer treatment Opdivo, saying Wednesday that co-developer Ono Pharmaceutical should pay him a higher percentage of profits than in their 2006 contract.
Companies
Nobel laureate demands higher cancer drug royalties from Ono Pharma
2018 winner in medicine plans to renegotiate contract for blockbuster Opdivo
Kyoto University professor Tasuku Honjo, left, speaking about his royalty payments for the revolutionary cancer drug Opdivo.
Read Next
Latest on Companies
